OMIC capitalization strongest level recorded by rating agency

We are pleased to report that OMIC continues to perform as one of the most fiscally sound insurance companies in America. Our results in 2024 showed policyholder growth that exceeded our year-end projections by a wide margin, surpassing 6,450 insured ophthalmologists.

OMIC’s strong balance sheet was referenced by the A.M. Best Company when they once again reaffirmed our “A” Excellent financial strength rating in 2025. See the report here. The rating reflects that OMIC has the "strongest level of risk-adjusted capitalization recorded by A.M. Best, as measured by Best's Capital Adequacy Ratio (BCAR)." A.M. Best recognized our long-term history of organic surplus growth despite substantial policyholder dividends that have significantly exceeded those of our industry peers for many years, and which are a function of our business model and commitment to our members.

One area of concern for the entire insurance industry is social inflation in the US. As defined by A.M. Best, this is the rise in current or future claims caused by higher court awards and legislated increases in claims payments driven by societal behavior, including changes in demographics, litigation financing, a perceived decay in the public trust of corporations, and changes in tort reform. Therefore, we strongly encourage members to contact their representatives to express the need for, and maintenance of, tort reform that limits severe malpractice settlements.

The continued availability of ophthalmic care depends on stability in the insurance market, which in turn depends on the prevention of increased settlement payments and "runaway" judgments.